ACS expands lung cancer screening eligibility to ages 50-80 with 20+ pack-years

Previous guideline was 55-74 with 30+ pack years

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Lung Cancer Awareness Month kicked off this week, and this is a monumental one for us at the American Cancer Society.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Robert A. Smith, PhD
Senior vice president, Early Cancer Detection Science, American Cancer Society
William L. Dahut, MD
Chief scientific officer, American Cancer Society
Table of Contents

YOU MAY BE INTERESTED IN

The tremendous promise—and potential peril—of the prostate-specific antigen (PSA) screening test have confounded guideline developers for decades. When introduced, PSA was one of the first and the only credible blood biomarkers for cancer screening. That a simple blood test should be used to screen for the most common cancer in men, one that was lethal for 3% of men and 5% of Black men, seemed like a slam dunk. 
 For nearly 30 years, the American Cancer Society’s prostate cancer screening guidelines have advised men to discuss prostate-specific antigen, or PSA, testing with a clinician and weigh potential benefits and harms, rather than treat screening as an unquestioned routine. This “informed decision-making” recommendation was consistent with guidelines from all major professional organizations in the United States, Canada, and Europe. 
In patients with extensive-stage small cell lung cancer, tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to the results of the phase III open-label, multicenter, randomized DeLLphi-305 study. 
Robert A. Smith, PhD
Senior vice president, Early Cancer Detection Science, American Cancer Society
William L. Dahut, MD
Chief scientific officer, American Cancer Society

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login